FDA grants priority review for Imfinzi in SCLC

FDA grants priority review for Imfinzi in SCLC
Image courtesy of AstraZeneca

Regulators in the US have accepted AstraZeneca’s supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC).

SCLC is an aggressive, fast-growing form of lung cancer that recurs and progresses rapidly despite initial response to platinum-based chemotherapy.

The sBLA was based on positive results from the Phase III CASPIAN trial published in The Lancet.

Results showed Imfinzi in combination with standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) vs. SoC.

The risk of death was reduced by 27% with median OS of 13.0 months for Imfinzi plus chemotherapy vs. 10.3 months for SoC. Results showed an estimated 33.9% of patients were alive at 18 months following treatment with Imfinzi plus chemotherapy vs. 24.7% of patients receiving SoC.

A Prescription Drug User Fee Act date is set for the first quarter of 2020.